• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, June 26 Strides Arcolab Ltd has informed the Bombay Stock Exchange that it has received ANDA (abbreviated new drug application) approvals for its famotidin injection in four dosages.

The stomach ulcer drug is licensed to its joint venture Akorn-Strides, LLC, is the ninth ANDA approval for sterile injectable products. The commercialisation will start shortly, Mr Arun Kumar, Strides group CEO and Vice-Chairman, said. The approval is for injections of 10 mg/ml; 2 ml, 4ml and 20 ml.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Stone India develops pantograph for double stack container trains

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line